ReviewProstate cancer2026
Burden of Treatment-Induced Vasomotor Symptoms in Men With Prostate Cancer on Androgen-Deprivation Therapy: A Systematic Literature Review.
Review in Prostate cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Androgen-deprivation therapy (ADT) for prostate cancer (PCa) is associated with vasomotor symptoms (VMS; hot flashes and night sweats). However, the impact of VMS has not been well characterized. This systematic literature review analyzed patient-reported outcome (PRO) instruments used to assess the quality of life (QoL) impact of ADT-induced VMS as well as the associated humanistic burden and epidemiology. Methods: MEDLINE In-Progress, Embase, Cochrane Database of Systematic Reviews (2011-2024), and major oncology and health economics and outcomes research conferences (2023-2024) were searched. Results: In total, 52 studies were included. Of 15 PRO instruments identified, the most common were the Hot Flash-Related Daily Interference Scale, the Expanded Prostate Index Composite-26, and hot flash daily diaries. No PRO instrument was specifically validated to assess the effect of ADT-induced VMS on QoL in PCa. VMS severity (including subjective burden) was significantly associated with QoL, whereas VMS frequency was not. However, no consensus exists on VMS severity definitions. VMS negatively affected sexual functioning, interpersonal relationships, and/or work productivity, and the associated anxiety, fatigue, insomnia, and poor sleep quality were found to impair QoL. VMS additionally appeared to mediate ADT's impact on sleep disturbance. ADT-induced VMS rates ranged from 1.4% to 68.9%, with higher frequencies reported within 3-6 months of ADT initiation and when adverse events were actively monitored or participants asked to report/record VMS events (30.7%-68.9%). Lower frequencies were seen when VMS were spontaneously captured or in retrospective analyses without active VMS monitoring/reporting (1.4%-15.8%) and with enzalutamide, apalutamide, and abiraterone as add-on therapy to ADT (13.9%-15.8%). Conclusions: VMS severity in men with PCa is more consistently associated with QoL impact versus VMS frequency. A need for PRO instruments specific to treatment-related VMS in PCa and a lack of consensus on definitions of severity for ADT-induced VMS in PCa were identified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.